News › Industry News, Patient Care

FDA Investigating Reports of Hospitalizations After Fake Ozempic

November 14, 2023
Hospital beds

At least three Americans have been reported hospitalized after using suspected counterfeits of semaglutide drugs, which include Novo Nordisk’s diabetes medication Ozempic, according to records released by the Food and Drug Administration.

Ozempic and Wegovy, another semaglutide medication from Novo Nordisk, have been in short supply for months amid booming sales for their use in weight loss.

The hospitalizations are among 42 reports to the FDA’s Adverse Event Reporting System that mention use of counterfeit semaglutide from around the world. The agency last updated its database at the end of last month to include reports tallied through the end of September.

Read more at CBS News >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Acquisition Lets AI and Operators Learn From Nearly $2 Billion in Annual Aesthetics Transactions
    • Galderma Celebrates 30 Years of Restylane
    • FDA Issues Letter to Evolus Over Jeuveau Social Media Promotion
    • North Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
Advertisement